Companies Dominating the West Syndrome Landscape
- Marinus Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- SK Biopharmaceuticals Co., Ltd.
- Alkem Laboratories Ltd.
- Supernus Pharmaceuticals, Inc.
- Eisai Co., Ltd.
- Abbott Laboratories
- Upsher-Smith Laboratories, LLC.
- Pfizer Inc.
- H. Lundbeck A/S
- UCB S.A.
Browse Key Market Insights with Data Illustration:
In the News
-
Eisai Co., Ltd. to announce its first presentation with Merck & Co., Inc. associated with the Phase 3 LEAP-002 trial investigating LENVIMA, a receptor tyrosine, orally available and discovered by Eisai. Furthermore, the anti-PD-1 therapy, plus KEYTRUSA, from Merck & Co., Inc., is also introduced as a first-line treatment for uHCC.
-
SK Biopharmaceuticals Co., Ltd. to announce the result of the long-term randomized open-label extension (OLE). The company is focused on treatment development for central nervous system (CNS) disorders. Data analyzed in the OLE phase was taken from nearly 335 adult patients having focal seizures. from nearly 355 adult patients having focal seizures.
